Allosteric modulators of g protein-coupled receptors

Current Topics in Medicinal Chemistry

Volumn 14, Issue 15, 2014, Pages 1735-1737

  Wells, Gregory J ^a  

^a Pennsylvania Drug Discovery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CELL MEMBRANE PROTEIN; CHLORDIAZEPOXIDE; CINACALCET; DIAZEPAM; FLURAZEPAM; G PROTEIN COUPLED RECEPTOR; MARAVIROC; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRAZEPAM; RADIOLIGAND; TEMAZEPAM; LIGAND; METABOTROPIC RECEPTOR; MOLECULAR LIBRARY; MUSCARINIC RECEPTOR;

ALCOHOL WITHDRAWAL; ALLOSTERISM; ALZHEIMER DISEASE; ANXIETY DISORDER; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG TARGETING; EDITORIAL; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPERPARATHYROIDISM; INFLAMMATION; MEDICINAL CHEMISTRY; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NEOPLASM; NONHUMAN; PARKINSON DISEASE; RECEPTOR BINDING; RECEPTOR BLOCKING; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY; BINDING SITE; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, MUSCARINIC; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921458817     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140826115952     Document Type: Editorial

References (33)

1. Stevens, C. W., Ed. G Protein-Coupled Receptors: Research and Methods in the Post-Genomic Era; Part 1; Humana Press: New York, 2014, pp. 3-22.
2. Millar, R.P.; Newton, C.L. The Year in G Protein-Coupled Receptors Research. Mol. Endocrinology, 2010, 24, 261-274.
3. Filmore D. It’s a GPCR world. Mod. Drug Discov. (ACS), 2004, 7, 24–28.
4. Hudson, B.D.; Ulven, T.; Milligan, G. The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. Curr. Topics Med. Chem., 2013, 13, 14-25.
5. Deupi, X., Kobilka, B.K., Energy Landscapes as a Tool to Integrate GPCR Structure, Dynamics, and Function. Amer. Physiol. Soc., 2010, 25, 293-303.
6. Dror, R.O.; Green, H.F.; Valant, C.; Borhani, D.W.; Valcourt, J.R.; Pan, A.C.; Arlow, D.H.; Canals, M.; Lane, J.R.; Rahmani, R.; Baell, J.B.; Sexton, P.M.; Christopoulos, A.; Shaw, D.E. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature, 2013, 503(7475), 295-299.
7. Valant, C.; Lane, J.R.; Sexton, P.M.; Christopoulos, A. The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein-Coupled Receptors. Ann. Rev. Pharmacol. Toxicol., 2012, 52, 153-178.
8. Kenakin, T.P. Biased signaling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol., 2012, 165(6), 1659-1669.
9. Melancon, B.J.; Hopkins, C.R.; Wood, M.R.; Emmitte, K.A.; Miswender, C.M.; Christopoulos, A.; Conn, P.J.; Lindsley, C.W. Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. J. Med. Chem., 2012, 55(4), 1445-1464.
10. May, L.T.; Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric Modulation of G Protein-Coupled Receptors. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51.
11. Jensen, A.A., Spalding, T. A. Allosteric modulation of G-protein coupled receptors. Eur. J. Pharm. Sci., 2004, 21, 407-420.
12. Yates, R.A.; Pardee, A.B. Pyrimidine biosynthesis in Escherichia coli. J. Biol. Chem., 1956, 221, 743–756
13. Pardee, A.B. Regulation, restriction, and reminiscences. J. Biol. Chem., 2002, 277, 26709–26716.
14. Umbarger, H.E. Evidence for a negative-feedback mechanism in the biosynthesis of isoleucine. Science, 1956, 123(3202), 848.
15. Monod, J.; Changeux, J.P.; Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol., 1963, 6, 306-329.
16. Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol., 1965, 12, 88-118.
17. Congreve, M.; Marshall, F. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharm. 2010, 159, 986-996.
18. Ballesteros, J.; Ranson, J. In-Target versus Off-Target allosteric modulators of GPCRs. Drug Discov. Today: Ther. Strateg., 2006, 3(4), 445-450.
19. Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn, P.J.; Lindsley, C.W. “Molecular switches” on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry, 2011, 50, 2403-2410.
20. Davey, A.E.; Leach, K.; Valant, C.; Conigrave, A.D.; Sexton, P.M.; Christopoulos, A. Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor. Endocrinology, 2012, 153(3), 1232-1241.
21. Gulick, R.M.; Lalezari, J; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J.B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S; Dunne, M.W.; van der Ryst, E.; Mayer, H. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. N. Eng. J. Med., 2008, 359, 1429-1441.
22. Garcia-Perez, J.; Rueda, P. Alcami, J.; Rognan, D.; Arenzana-Selsdedos, F.; Lagane, B.; Kellenberger, E. Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J. Biol. Chem. 2011, 286(38), 33409-33421.
23. Nickols, H.H.; Conn, P.J. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis., 2013, 61, 55-71.
24. Conn, P.J.; Kuduk, S.D.; Doller, D. Drug Design Strategies for GPCR Allosteric Modulators. In: Annual Reports in Medicinal Chemistry; Desai, M.C., Bernstein, P.R., Eds.; Elsevier; Waltham, MA, 2012; pp 441-457.
25. Kuduk, S. K.; Beshore, D.C. SAR Studies on Carboxylic Acid Series M1 Selective Positive Allosteric Modulators (PAMs). Curr. Top. Med. Chem. 2014, 14(15), 1738-1754.
26. Huang, X.; Dale, E.; Brodbeck, R.M.; Doller, D. Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities. Curr. Top. Med. Chem., 2014, 14(15), 1755-1770.
27. Szabó, G.; Keser_, G.M. Positive allosteric modulators for mGluR2 receptors: a medicinal chemistry perspective. Curr. Top. Med. Chem., 2014, 14(15), 1771-1788.
28. Hao, J.; Xiong, H. SAR Studies on mGlu5 Receptor Positive Allosteric Modulators (2003-2013). Curr. Top. Med. Chem., 2014, 14(15), 1789-1841.
29. Hurevich, M.; Gilon, C. Dimerization Inhibitors as Allosteric Modulators of GPCR: the chemokine receptors paradigm. Curr. Top. Med. Chem., 2014, 14(15), 1842-1863.
30. Csermely, P.; Nussinov, R.; Szilagyi, A. From Allosteric Drugs to Allo-Network Drugs: State of the Art and Trends of Design, Synthesis, and Computational Methods. Curr. Top. Med. Chem., 2013, 13, 1-4.
31. Rocher, J-P.; Bonnet, B.; Bolea, C.; Lutjens, R.; Le Poul, E.; Poli, S.; Epping-Jordan, M.; Bessis, A-S.; Ludwig, B.; Mutel, V. mGlu5 Negative Allosteric Modulators Overview: A Medicinal Chemistry Approach Towards a Series of Novel Therapeutic Agents. Curr. Top. Med. Chem., 2011, 11, 680-695.
32. Overington J.P.; Al-Lazikani B.; Hopkins A.L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5 (12), 993-6.
33. Granier, S.; Kobilka, B. A new era of GPCR structural and chemical biology. Nat. Chem. Biol., 2012, 8, 670-673.